SGLT-2抑制剂对2型糖尿病肾病患者的心血管保护作用  

Cardiovascular protective effects of SGLT-2 inhibitors on patients with type 2 diabetic nephropathy

作　　者：桑亚菲 袁静雅 赵倩[1] 王佳琳 马瑜瑾[1] 王宏运[1] SANG Ya-fei;YUAN Jing-ya;ZHAO Qian;WANG Jia-lin;MA Yu-jin;WANG Hong-yun(Department of Endocrinology,First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,471003,China)

机构地区：[1]河南科技大学第一附属医院内分泌科,河南洛阳471003

出　　处：《心血管康复医学杂志》2024年第4期449-455,共7页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探究钠-葡萄糖共转运蛋白2抑制剂(SGLT-2i)治疗2型糖尿病肾病患者的临床疗效及心血管保护作用。方法:选择2018年1月到2021年12月于我院内分泌科、心血管内科住院的2型糖尿病肾病患者376例,按治疗方案的不同分为对照组(177例,采用常规治疗方案)和SGLT-2i组(199例,在常规治疗方案的基础上联合使用SGLT-2i),且两组患者持续治疗1年。对比两组患者治疗12个月后血糖、血压、血脂、尿酸、人体质量指数、肾功能相关指标及主要不良心血管事件的发生情况,并记录药物的不良反应。结果:治疗12个月后,与对照组比较,SGLT-2i组的血压、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、尿微量白蛋白/肌酐(UACR)、肌酐(Cr)、尿素氮(BUN)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、尿酸(UA)水平均显著降低,估算的肾小球滤过率(eGFR)、高密度脂蛋白胆固醇(HDL-C)、白蛋白(Alb)、丙氨酸氨基转移酶(ALT)水平均显著升高(P<0.05或<0.01)。SGLT-2i组的急性心肌梗死(1.51%比6.21%)、因心力衰竭住院的发生率(2.51%比6.78%)均显著低于对照组,泌尿系感染的发生率(8.54%比1.69%)显著高于对照组(P均<0.05)。结论:SGLT-2i不仅能有效控制血糖,而且还有减轻体重、降低血压、改善血脂、降低尿酸、改善肾脏高滤过、减少尿蛋白的作用以及特有的心血管获益优势,但需注意泌尿系统感染风险。Objective:To explore the clinical efficacy and cardiovascular protective effect of sodium-glucose co-transporter 2 inhibitor(SGLT-2i)on patients with type 2 diabetic nephropathy(T2DN).Methods:A total of 376 T2DN patients admitted in our Department of Endocrinology and Department of Cardiology from January 2018 to December 2021 were selected.According to therapeutic program,they were divided into control group(n=177,received routine treatment program)and SGLT-2i group(n=199,received SGLT-2i based on routine treatment program),both groups were continuously treated for 1 year.Blood glucose,blood pressure,blood lipids,uric acid,body mass index,renal function-related indexes and the occurrence of major adverse cardiovascular events were compared between the two groups after 12 months,as well as the adverse drug reactions.Results:After 12-month treatment,compared with control group,there were significant reductions in levels of blood pressure,fasting blood glucose(FBG),glycosylated hemoglobin A1c(HbA1c),urinary albumin/creatinine ratio(UACR),creatinine(Cr),blood urea nitrogen(BUN),total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and uric acid(UA),and significant rise in estimated glomerular filtration rate(eGFR),levels of high density lipoprotein cholesterol(HDL-C),albumin(Alb)and alanine aminotransferase(ALT)in SGLT-2i group(P<0.05 or<0.01).Incidence rates of acute myocardial infarction(1.51%vs.6.21%)and heart failure caused-readmission(2.51%vs.6.78%)in SGLT-2i group were significantly lower than those of control group,and incidence rate of urinary system infection(8.54%vs.1.69%)was significantly higher than that of control group(P<0.05 all).Conclusion:SGLT-2i can not only effectively control blood glucose,but also reduce body weight and blood pressure,improve blood lipids,reduce uric acid,improve renal hyperfiltration,reduce urinary protein and possess unique cardiovascular benefits,but risk of urinary system infection calls for attention.

关 键 词：糖尿病肾病 钠-葡萄糖转运体2 心血管系统 

分 类 号：R587.24[医药卫生—内分泌]